Among the new generation of glucose-lowering oral drugs, inhibitors of the sodium-glucose cotransporter 2 (SGLT2) have been identified to have a potential role in lowering the risk of renal complications in patients with diabetes [12,13,14,15,16]. Here, SLC5A2 is linked to diabetes mellitus.